Study guide

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification

Key Takeaways Explain This Topic AI

Abnormal uterine bleeding (AUB) is classified by the FIGO PALM-COEIN system into structural causes (Polyp, Adenomyosis, Leiomyoma, Malignancy) and non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not otherwise classified).

A urine or serum human chorionic gonadotropin (hCG) test is the mandatory first-line diagnostic investigation for any patient of reproductive age presenting with abnormal bleeding.

Endometrial biopsy is indicated for all individuals aged 45 years and older with AUB, and for individuals under 45 with chronic unopposed estrogen exposure (e.g., obesity, PCOS), persistent bleeding, or failed medical management.

First-line long-term medical management for heavy menstrual bleeding without structural cavity distortion includes the 52 mg levonorgestrel intrauterine system (LNG-IUS) or combined oral contraceptives; acute severe bleeding is stabilized with high-dose oral progestins, tranexamic acid, or intravenous conjugated equine estrogen.

Last updated: October 2026

Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification

Important

A urine or serum human chorionic gonadotropin (hCG) test is the mandatory first-line diagnostic investigation for any patient of reproductive age presenting with abnormal uterine bleeding, regardless of contraceptive history. Ectopic pregnancy and gestational trophoblastic disease must be excluded before pursuing other etiologies.

Defining Normal and Abnormal Uterine Bleeding

Abnormal uterine bleeding (AUB) encompasses any variation from normal menstrual cyclicity, regularity, duration, or volume in non-pregnant reproductive-age individuals. The International Federation of Gynecology and Obstetrics (FIGO) replaced ambiguous terms like menorrhagia and metrorrhagia with standardized parameters:

  • Menstrual Parameter Normal Reference Range Abnormal Clinical Definition
  • Frequency 24 to 38 days Frequent (<24 days) or Infrequent (>38 days)
  • Regularity Cycle variation ≤7 to 9 days Irregular (variation >8 to 10 days) or Absent
  • Duration Up to 8 days Prolonged (>8 days); FIGO 2018 dropped the 'shortened' category
  • Volume Manageable flow Heavy menstrual bleeding (HMB) or Light flow

Heavy menstrual bleeding (HMB) is defined as excessive blood loss interfering with physical, social, or emotional quality of life. Indicators include soaking ≥1 pad or tampon every hour for two consecutive hours, waking to change protection, passing clots >2.5 cm, or iron deficiency anemia. AUB is categorized into acute AUB (severe bleeding requiring immediate clinical intervention) and chronic AUB (bleeding abnormal in duration, volume, or frequency for the majority of the preceding 6 months).

The FIGO PALM-COEIN Classification System

FIGO classifies AUB into structural causes (PALM) identified on imaging or histology, and non-structural causes (COEIN) representing systemic or functional processes:

Structural Etiologies (PALM)

Polyp (AUB-P) : Hyperplastic overgrowths of endometrial glands and stroma around a vascular stalk. Polyps frequently produce intermenstrual spotting or HMB. Diagnosis is confirmed by transvaginal ultrasound (TVUS) or saline infusion sonohysterography (SIS), with hysteroscopic resection providing definitive therapy.

Adenomyosis (AUB-A) : Ectopic endometrial glands and stroma within the myometrium causing reactive smooth muscle hypertrophy. Clinically, patients present with HMB, dysmenorrhea, and a symmetrically enlarged, globular, "boggy," tender uterus. Ultrasound shows asymmetric myometrial thickening, subendometrial cysts, and junctional zone thickening ≥12 mm on MRI.

Leiomyoma (AUB-L) : Monoclonal smooth muscle tumors. FIGO stratifies fibroids into submucosal (L_SM) (Types 0–2), which distort the endometrial cavity and drive severe HMB, and other (L_O) (Types 3–8), which produce pelvic bulk symptoms, pelvic pressure, and urinary frequency.

Malignancy & Hyperplasia (AUB-M) : Atypical endometrial hyperplasia and adenocarcinoma must be excluded in high-risk patients, especially those aged ≥45 years or with chronic unopposed estrogen exposure.

Non-Structural Etiologies (COEIN)

Coagulopathy (AUB-C) : Encompasses systemic bleeding disorders. Von Willebrand disease (vWD) is the most common inherited coagulopathy, present in up to 20% of adolescents hospitalized for severe AUB. A structured screening tool is positive with heavy menses since menarche, postpartum hemorrhage, dental extraction bleeding, or frequent epistaxis.

Ovulatory Dysfunction (AUB-O) : Anovulatory cycles lead to absent luteal progesterone. Unopposed estrogen promotes persistent endometrial proliferation, resulting in fragile tissue breakdown with irregular, heavy bleeding. Causes include polycystic ovary syndrome (PCOS), perimenopause, adolescent HPO axis immaturity, thyroid disease, and hyperprolactinemia.

Endometrial (AUB-E) : Manifests in patients with regular ovulatory cycles experiencing HMB without structural lesions. It reflects primary endometrial dysfunction, such as deficient local vasoconstrictors (PGF2-alpha, endothelin-1) or accelerated fibrinolysis from excess tissue plasminogen activator.

Iatrogenic (AUB-I) : Bleeding induced by medical interventions, including copper IUDs, unscheduled spotting from progestin implants/IUS, combined contraceptives, systemic anticoagulants, or psychotropic medications.

Not Otherwise Classified (AUB-N) : Rare entities including uterine arteriovenous malformations (AVMs), myometrial hypertrophy, and cesarean scar defects (isthmocele or niche). FIGO 2018 places chronic endometritis under AUB-E.

Diagnostic Evaluation & Biopsy Indications

Laboratory Testing :

Urine or serum hCG (mandatory first line).

Complete blood count (CBC) to quantify anemia and thrombocytopenia.

Serum ferritin to detect depleted iron stores.

TSH and prolactin to rule out ovulatory endocrinopathies.

Coagulation panel (PT, aPTT, fibrinogen, vWF antigen, ristocetin cofactor) for adolescents with heavy bleeding since menarche or positive screening history.

Pelvic Imaging :

Transvaginal Pelvic Ultrasound (TVUS) : Initial non-invasive modality to evaluate endometrial thickness, myometrial architecture, and adnexa.

Saline Infusion Sonohysterography (SIS) : Superior to TVUS for delineating focal intracavitary polyps and submucosal fibroids.

Note

Endometrial Biopsy (EMB) Indications :

All individuals aged ≥45 years presenting with abnormal uterine bleeding.

Individuals aged <45 years with chronic unopposed estrogen exposure (e.g., obesity with BMI ≥30, PCOS, chronic anovulation).

Individuals aged <45 years with persistent bleeding, intermenstrual spotting, or failed medical therapy.

Any postmenopausal bleeding with an endometrial stripe >4 mm on TVUS, or persistent bleeding regardless of stripe thickness.

  • Management: Acute vs. Chronic AUB
  • Acute Severe AUB Management

When acute, heavy uterine hemorrhage occurs without hemodynamic collapse, medical stabilization is prioritized:

Intravenous Conjugated Equine Estrogen (CEE) : 25 mg IV every 4 to 6 hours for up to 24 hours. CEE induces rapid endometrial proliferation and local vasospasm to arrest hemorrhage.

High-Dose Oral Progestins : Medroxyprogesterone acetate 20 mg PO three times daily for 7 days (ACOG Committee Opinion 557).

Combined Oral Contraceptives (COCs) : A monophasic 35 mcg ethinyl estradiol pill three times daily for 7 days (ACOG Committee Opinion 557), after screening for estrogen contraindications.

Tranexamic Acid (TXA) : 1.3 g PO three times daily for 5 days, or 10 mg/kg IV (maximum 600 mg per dose) every 8 hours. TXA is an antifibrinolytic that stabilizes clots; contraindicated in active thromboembolic disease.

Mechanical Tamponade & Surgery : An intrauterine Foley catheter balloon inflated with 30 to 50 mL sterile saline provides direct mechanical tamponade. Emergent dilation and curettage (D&C) is reserved for hemodynamic instability or failure of medical stabilization.

Chronic AUB Management

Levonorgestrel 52 mg IUS : Most effective first-line non-surgical therapy for HMB, reducing blood loss by 70% to 90% at 6 months through profound local endometrial atrophy.

Combined Hormonal Contraceptives : Suppress ovulation and thin the endometrium, reducing dysmenorrhea and blood loss.

Oral Progestins : Daily norethindrone (5 mg) or medroxyprogesterone acetate (10 mg) prescribed continuously or during the luteal phase (days 14–25) prevents endometrial hyperplasia in anovulatory bleeding (AUB-O).

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) : Ibuprofen (600–800 mg TID) during menses inhibits cyclooxygenase, reducing menstrual flow by 25% to 40%.

Surgical Modalities : Endometrial ablation (only for completed childbearing with a normal uterine cavity); myomectomy (hysteroscopic for Type 0/1 submucosal fibroids; laparoscopic/abdominal for other fibroids desiring uterine conservation); and hysterectomy (definitive cure for completed childbearing refractory to medical therapy).